サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1436479

髄膜炎菌ワクチンの世界市場レポート 2024

Meningococcal Vaccines Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 175 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
髄膜炎菌ワクチンの世界市場レポート 2024
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

髄膜炎菌ワクチンの市場規模は、今後数年間で大幅な成長が見込まれています。 2028年には9.6%の年間複合成長率（CAGR）で56億9,000万米ドルに成長すると予想されます。予測期間中に予想される成長は、新種の病気の出現、世界化の増加傾向、ヘルスケアへの投資の増加、ワクチン接種を促進する医療への取り組み、規制状況。この期間中に予想される主な動向には、個別化ワクチンの開発、デジタルワクチン接種記録の採用、ワクチン開発のための遺伝子編集技術の進歩、多価ワクチンの利用、ワクチンの配布とアクセスのためのサブスクリプションベースのモデルの探求が含まれます。

予想されるヘルスケア費の増加により、髄膜炎菌ワクチン市場は将来的に拡大する見込みです。ヘルスケアには、住宅介護施設、介護施設、精神疾患のある人のための中間介護施設、精神薄弱な人のための中間介護施設など、さまざまな施設が含まれます。前世代と比較して新しい世代のワクチンのコストが上昇していることは、これらの新しいワクチンの利点がその価格に見合うかどうかに関する議論の焦点となっています。ワクチン接種の包括的な社会的および経済的利点を評価することは、ワクチン接種の価値に関する文献においてますます重要な研究分野になりつつあります。 例えば、2022年5月、米国の専門家団体で医師や医学生によるロビー団体である米国医師会が発表した記事によると、米国の医療費は9.7％増の4兆1,000億米ドルに急増し、1人当たり12,530ドルに達しました。この伸び率は2019年の4.3％を大きく上回っている。その結果、医療支出の増加が髄膜炎菌ワクチン市場の成長を促進しています。

髄膜炎菌性疾患の発生率の上昇により、将来的に髄膜炎菌ワクチン市場の成長が促進されると予想されます。髄膜炎菌性疾患は、髄膜炎菌によって引き起こされる重度の細菌感染症であり、髄膜炎（脳と脊髄を取り囲む膜の炎症）や敗血症（血流感染症）を引き起こす可能性があります。 髄膜炎菌ワクチンは、髄膜炎菌によって引き起こされる髄膜炎菌性疾患の予防に非常に効果的です。たとえば、2023年9月、公衆衛生を専門とする南オーストラリア州の政府機関であるSA Healthは、侵襲性髄膜炎菌性疾患の20例を報告し、そのうち17例は血清群Bに関連し、3例は血清群Wに関連していました。これは、過去の報告からの増加を意味します。 2022年には14件の症例が報告されました。したがって、髄膜炎菌性疾患の発生率の増加は、髄膜炎菌性ワクチン市場の成長の主要な推進力です。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年～2023年
  • 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

  • 世界の髄膜炎菌ワクチン市場、ワクチンタイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 髄膜炎菌結合型ワクチン
  • 多糖類
  • 被膜下ワクチン
  • 世界の髄膜炎菌ワクチン市場、血清型別のセグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • Men ACWY
  • Men B または BC
  • Men C
  • 世界の髄膜炎菌ワクチン市場、年齢層別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 幼児
  • 子供
  • 青少年およびヤングアダルト
  • 大人
  • 世界の髄膜炎菌ワクチン市場、流通チャネル別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 薬局
  • 地域診療所
  • 公衆衛生機関
  • 他のチャンネル
  • 世界の髄膜炎菌ワクチン市場、エンドユーザー別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 病院
  • 研究
  • 学術機関

第7章 地域および国の分析

  • 世界の髄膜炎菌ワクチン市場、地域別、実績および予測、2018-2023、2023-2028年、2033年
  • 世界の髄膜炎菌ワクチン市場、国別、実績および予測、2018-2023、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 髄膜炎菌ワクチン市場の競合情勢
  • 髄膜炎菌ワクチン市場の企業プロファイル
    • Pfizer Inc.
    • Johnson and Johnson Services Inc.
    • Sinopharm Group Co. Ltd.
    • Merck &Co. Inc.
    • Novartis AG

第31章 その他の主要および革新的な企業

  • Sanofi SA
  • AstraZeneca plc
  • GlaxoSmithKline plc
  • Takeda Pharmaceutical Company Limited
  • Baxter International Inc.
  • CSL Limited
  • Seqirus Pty Ltd.
  • Sinovac Biotech Ltd.
  • Emergent BioSolutions Inc.
  • Walvax Biotechnology Co. Ltd.
  • Hualan Biological Engineering Inc.
  • Beximco Pharmaceuticals Ltd.
  • Bavarian Nordic A/S
  • JN-International Medical Corporation
  • Valneva SE

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

目次
Product Code: r15812

Meningococcal vaccinations are vaccines designed to protect against meningococcal meningitis, an infection caused by the bacterium Neisseria meningitidis, which can lead to inflammation of the membranes covering the brain and spinal cord.

Meningococcal vaccines come in several types, including meningococcal conjugate, polysaccharide, and subcapsular vaccines. Meningococcal conjugate vaccines combine a polysaccharide antigen with a carrier molecule. Different serotypes are available, such as Men ACWY, Men B or BC, and Men C, targeting infants, children, adolescents, young adults, and adults. These vaccines are distributed through pharmacies, community clinics, public health agencies, and other outlets, serving end-users such as hospitals, research institutions, and academic institutes.

The meningococcal vaccines market research report is one of a series of new reports from The Business Research Company that provides meningococcal vaccines market statistics, including the meningococcal vaccines industry's global market size, regional shares, competitors with a meningococcal vaccines market share, detailed meningococcal vaccines market segments, market trends and opportunities, and any further data you may need to thrive in the meningococcal vaccines industry. The meningococcal vaccines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The meningococcal vaccines market size has grown rapidly in recent years. It will grow from $3.57 billion in 2023 to $3.94 billion in 2024 at a compound annual growth rate (CAGR) of 10.5%. The growth during the historical period can be attributed to factors such as disease incidence, trends in global travel, the state of healthcare infrastructure, preparedness for epidemics, and the extent of health insurance coverage available.

The meningococcal vaccines market size is expected to see strong growth in the next few years. It will grow to $5.69 billion in 2028 at a compound annual growth rate (CAGR) of 9.6%. The expected growth in the forecast period is influenced by several factors: the emergence of new strains of diseases, the increasing trend of globalization, rising investments in healthcare, health initiatives promoting vaccination, and changes in the regulatory landscape. Key trends anticipated during this period encompass the development of personalized vaccines, the adoption of digital vaccination records, advancements in gene editing technologies for vaccine development, the utilization of multi-valent vaccines, and the exploration of subscription-based models for vaccine distribution and access.

The anticipated rise in healthcare expenditure is poised to drive the expansion of the meningococcal vaccine market in the future. Healthcare encompasses various facilities such as residential care institutions, nursing facilities, intermediate care facilities for individuals with mental illnesses, or intermediate care facilities for individuals with mental retardation. The increasing cost of new vaccine generations compared to their predecessors has become a focal point in debates regarding whether the benefits of these new vaccines justify their prices. Evaluating the comprehensive social and economic benefits of vaccination is becoming an increasingly vital area of study in the literature on the value of vaccination. For example, in May 2022, an article published by the American Medical Association, a US-based professional association and lobbying group of physicians and medical students, reported that healthcare spending in the United States had surged by 9.7% to $4.1 trillion, amounting to $12,530 per person. This growth rate is significantly higher than that of 2019, which was 4.3%. Consequently, the increase in healthcare spending is propelling the growth of the meningococcal vaccine market.

The rising incidence of meningococcal disease is expected to drive the growth of the meningococcal vaccine market in the future. Meningococcal disease is a severe bacterial infection caused by Neisseria meningitidis, which can lead to meningitis (inflammation of the membranes surrounding the brain and spinal cord) and septicemia (bloodstream infection). Meningococcal vaccines are highly effective in preventing meningococcal disease caused by Neisseria meningitidis. For example, in September 2023, SA Health, a government agency in South Australia focused on public health, reported 20 instances of invasive meningococcal disease, with 17 cases associated with serogroup B and three cases linked to serogroup W. This represents an increase from the 14 cases reported in 2022. Therefore, the rising incidence of meningococcal disease is a key driver of the growth of the meningococcal vaccine market.

Key players in the meningococcal vaccines market are actively engaged in the development of new vaccines targeting various serogroups, aiming to enhance their market profitability. Meningococcal vaccines serve as preventive measures, guarding individuals against infections caused by specific serogroups of the Neisseria meningitidis bacteria. Notably, in October 2023, Pfizer Inc., a renowned US-based pharmaceutical company, obtained FDA approval for its vaccine, PENBRAYA. Distinguished by its extensive serogroup coverage, PENBRAYA stands as the most comprehensive meningococcal vaccine sanctioned in the United States, providing protection against serogroups A, B, C, W, and Y. The FDA's endorsement of PENBRAYA is supported by robust Phase 2 and 3 trial data, affirming its non-inferior immunogenicity when compared to Trumenba + Menveo across all targeted serogroups, coupled with favorable safety profiles. Additionally, Pfizer's September 2022 announcement highlighted positive outcomes from a Phase 3 trial, showcasing PENBRAYA's safety, tolerability, and immunogenicity compared to existing licensed meningococcal vaccines.

Major companies in the meningococcal vaccines market are strategically engaging in partnerships to bolster their profitability within the market. These collaborations involve cooperative efforts among pharmaceutical firms, research institutions, government bodies, and non-profit organizations, aimed at collectively advancing the development, production, distribution, or enhancement of meningococcal vaccines. For instance, in July 2023, the Serum Institute of India, a biotechnology company based in India, partnered with PATH, a US-based non-profit health organization, to develop MenFive. The Serum Institute of India received WHO prequalification for MenFive, a multivalent meningococcal meningitis vaccine. MenFive stands as the first conjugate vaccine of its kind, targeting the primary causes of meningococcal meningitis prevalent in Africa. This vaccine follows the success of MenAfriVac, introduced in 2010, which successfully eradicated serogroup A meningococcal meningitis outbreaks in the African meningitis belt. MenFive is designed to prevent fatalities and disabilities caused by the disease. The Serum Institute of India's groundbreaking vaccines contribute significantly to the ongoing fight against meningococcal meningitis in Africa.

In August 2022, GlaxoSmithKline PLC, a pharmaceutical and biotechnology company headquartered in the UK, completed the acquisition of Affinivax Inc. for $3.3 billion. GSK's acquisition of Affinivax aligns with its strategic goal of building a diverse portfolio encompassing specialty medicines and vaccines. Affinivax, Inc., based in the US, specializes in next-generation vaccine technology and operates within the meningococcal vaccines sector.

Major companies operating in the meningococcal vaccines market report are Pfizer Inc., Johnson and Johnson Services Inc., Sinopharm Group Co. Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Baxter International Inc., CSL Limited, Seqirus Pty Ltd., Sinovac Biotech Ltd., Emergent BioSolutions Inc., Walvax Biotechnology Co. Ltd., Hualan Biological Engineering Inc., Beximco Pharmaceuticals Ltd., Bavarian Nordic A/S, JN-International Medical Corporation, Valneva SE, Serum Institute of India Pvt. Ltd., Incepta Pharmaceuticals Ltd., Biological E. Limited, LG Chem Life Sciences Company, Chongqing Zhifei Biological Products Co., Protein Sciences Corporation, Bharat Biotech Ltd., Bio-Med Limited, Bio-Manguinhos, Nuron Biotech Ltd.

North America was the largest region in the meningococcal vaccines market in 2023. Asia-Pacific is expected to be the fastest-growing region in the meningococcal vaccines market report during the forecast period. The regions covered in the meningococcal vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the meningococcal vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The meningococcal vaccines market consists of sales of conjugate vaccines, combination vaccines, serogroup B vaccine products, and other types. Values in this market are 'pharmaceuticals' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Meningococcal Vaccines Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on meningococcal vaccines market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for meningococcal vaccines ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The meningococcal vaccines market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Vaccine Type: Meningococcal Conjugate Vaccine; Polysaccharide; Subcapsular Vaccine
  • 2) By Serotype: Men ACWY; Men B Or BC; Men C
  • 3) By Age Group: Infants; Children; Adolescents and Young Adults; Adults
  • 4) By Distribution Channel: Pharmacies; Community Clinics; Public Health Agencies; Other Channels
  • 5) By End user: Hospitals; Research; Academic Institutes
  • Companies Mentioned: Pfizer Inc.; Johnson and Johnson Services Inc.; Sinopharm Group Co. Ltd.; Merck & Co. Inc.; Novartis AG
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Meningococcal Vaccines Market Characteristics

3. Meningococcal Vaccines Market Trends And Strategies

4. Meningococcal Vaccines Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Meningococcal Vaccines Market Size and Growth

  • 5.1. Global Meningococcal Vaccines Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Meningococcal Vaccines Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Meningococcal Vaccines Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Meningococcal Vaccines Market Segmentation

  • 6.1. Global Meningococcal Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Meningococcal Conjugate Vaccine
  • Polysaccharide
  • Subcapsular Vaccine
  • 6.2. Global Meningococcal Vaccines Market, Segmentation By Serotype, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Men ACWY
  • Men B Or BC
  • Men C
  • 6.3. Global Meningococcal Vaccines Market, Segmentation By Age Group, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Infants
  • Children
  • Adolescents and Young Adults
  • Adults
  • 6.4. Global Meningococcal Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Pharmacies
  • Community Clinics
  • Public Health Agencies
  • Other Channels
  • 6.5. Global Meningococcal Vaccines Market, Segmentation By End user, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Research
  • Academic Institutes

7. Meningococcal Vaccines Market Regional And Country Analysis

  • 7.1. Global Meningococcal Vaccines Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Meningococcal Vaccines Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Meningococcal Vaccines Market

  • 8.1. Asia-Pacific Meningococcal Vaccines Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Meningococcal Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Meningococcal Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Meningococcal Vaccines Market, Segmentation By End user, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Meningococcal Vaccines Market

  • 9.1. China Meningococcal Vaccines Market Overview
  • 9.2. China Meningococcal Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Meningococcal Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Meningococcal Vaccines Market, Segmentation By End user, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Meningococcal Vaccines Market

  • 10.1. India Meningococcal Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Meningococcal Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Meningococcal Vaccines Market, Segmentation By End user, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Meningococcal Vaccines Market

  • 11.1. Japan Meningococcal Vaccines Market Overview
  • 11.2. Japan Meningococcal Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Meningococcal Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Meningococcal Vaccines Market, Segmentation By End user, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Meningococcal Vaccines Market

  • 12.1. Australia Meningococcal Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Meningococcal Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Meningococcal Vaccines Market, Segmentation By End user, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Meningococcal Vaccines Market

  • 13.1. Indonesia Meningococcal Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Meningococcal Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Meningococcal Vaccines Market, Segmentation By End user, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Meningococcal Vaccines Market

  • 14.1. South Korea Meningococcal Vaccines Market Overview
  • 14.2. South Korea Meningococcal Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Meningococcal Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Meningococcal Vaccines Market, Segmentation By End user, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Meningococcal Vaccines Market

  • 15.1. Western Europe Meningococcal Vaccines Market Overview
  • 15.2. Western Europe Meningococcal Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Meningococcal Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Meningococcal Vaccines Market, Segmentation By End user, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Meningococcal Vaccines Market

  • 16.1. UK Meningococcal Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Meningococcal Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Meningococcal Vaccines Market, Segmentation By End user, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Meningococcal Vaccines Market

  • 17.1. Germany Meningococcal Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Meningococcal Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Meningococcal Vaccines Market, Segmentation By End user, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Meningococcal Vaccines Market

  • 18.1. France Meningococcal Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Meningococcal Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Meningococcal Vaccines Market, Segmentation By End user, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Meningococcal Vaccines Market

  • 19.1. Italy Meningococcal Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Meningococcal Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Meningococcal Vaccines Market, Segmentation By End user, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Meningococcal Vaccines Market

  • 20.1. Spain Meningococcal Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Meningococcal Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Meningococcal Vaccines Market, Segmentation By End user, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Meningococcal Vaccines Market

  • 21.1. Eastern Europe Meningococcal Vaccines Market Overview
  • 21.2. Eastern Europe Meningococcal Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Meningococcal Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Meningococcal Vaccines Market, Segmentation By End user, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Meningococcal Vaccines Market

  • 22.1. Russia Meningococcal Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Meningococcal Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Meningococcal Vaccines Market, Segmentation By End user, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Meningococcal Vaccines Market

  • 23.1. North America Meningococcal Vaccines Market Overview
  • 23.2. North America Meningococcal Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Meningococcal Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Meningococcal Vaccines Market, Segmentation By End user, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Meningococcal Vaccines Market

  • 24.1. USA Meningococcal Vaccines Market Overview
  • 24.2. USA Meningococcal Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Meningococcal Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Meningococcal Vaccines Market, Segmentation By End user, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Meningococcal Vaccines Market

  • 25.1. Canada Meningococcal Vaccines Market Overview
  • 25.2. Canada Meningococcal Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Meningococcal Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Meningococcal Vaccines Market, Segmentation By End user, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Meningococcal Vaccines Market

  • 26.1. South America Meningococcal Vaccines Market Overview
  • 26.2. South America Meningococcal Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Meningococcal Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Meningococcal Vaccines Market, Segmentation By End user, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Meningococcal Vaccines Market

  • 27.1. Brazil Meningococcal Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Meningococcal Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Meningococcal Vaccines Market, Segmentation By End user, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Meningococcal Vaccines Market

  • 28.1. Middle East Meningococcal Vaccines Market Overview
  • 28.2. Middle East Meningococcal Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Meningococcal Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Meningococcal Vaccines Market, Segmentation By End user, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Meningococcal Vaccines Market

  • 29.1. Africa Meningococcal Vaccines Market Overview
  • 29.2. Africa Meningococcal Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Meningococcal Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Meningococcal Vaccines Market, Segmentation By End user, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Meningococcal Vaccines Market Competitive Landscape And Company Profiles

  • 30.1. Meningococcal Vaccines Market Competitive Landscape
  • 30.2. Meningococcal Vaccines Market Company Profiles
    • 30.2.1. Pfizer Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Johnson and Johnson Services Inc.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Sinopharm Group Co. Ltd.
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Merck & Co. Inc.
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Novartis AG
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Meningococcal Vaccines Market Other Major And Innovative Companies

  • 31.1. Sanofi S.A
  • 31.2. AstraZeneca plc
  • 31.3. GlaxoSmithKline plc
  • 31.4. Takeda Pharmaceutical Company Limited
  • 31.5. Baxter International Inc.
  • 31.6. CSL Limited
  • 31.7. Seqirus Pty Ltd.
  • 31.8. Sinovac Biotech Ltd.
  • 31.9. Emergent BioSolutions Inc.
  • 31.10. Walvax Biotechnology Co. Ltd.
  • 31.11. Hualan Biological Engineering Inc.
  • 31.12. Beximco Pharmaceuticals Ltd.
  • 31.13. Bavarian Nordic A/S
  • 31.14. JN-International Medical Corporation
  • 31.15. Valneva SE

32. Global Meningococcal Vaccines Market Competitive Benchmarking

33. Global Meningococcal Vaccines Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Meningococcal Vaccines Market

35. Meningococcal Vaccines Market Future Outlook and Potential Analysis

  • 35.1 Meningococcal Vaccines Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Meningococcal Vaccines Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Meningococcal Vaccines Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer